Biotech entity
Zacks is most often covered alongside Aligos Therapeutics, which appears in 1 of these 2 stories. Across a 14-day span, the pace is roughly 1 story per week. They are less corroborated than the beat average, carrying 2 original sources each against 2.1 for the same window.
Last mentioned: 1d ago
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Zacks is most often covered alongside Aligos Therapeutics, which appears in 1 of these 2 stories. Across a 14-day span, the pace is roughly 1 story per week. They are less corroborated than the beat average, carrying 2 original sources each against 2.1 for the same window. Coverage clusters in clinical-trial, which accounts for 1 of those 2, with the remainder spread across 1 other category. Their average consequence score of 5 runs below the beat's 5.5 for that window. Zacks appears in 2 tracked Biotech stories published from August 9, 2026 through August 22, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 69 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Zacks. Shared-story counts are live from our verified record — not editorial picks.
I-Mab, a clinical-stage oncology and immunology biotech, reported a $(0.16) quarterly EPS on Aug 20. With shares at $1.91, H.C. Wainwright's reiterated $9 target implies massive upside, though Weiss remains bearish. Institutional ownership sits at 38.38%.
Source: Bbns · Ticker Report
Aligos Therapeutics (ALGS) handily beat Q2 consensus earnings per share by $0.95, a significant outperformance for the clinical-stage biotech. This beat may reflect operational efficiencies, milestone payments, or clinical progress in its liver disease pipeline. Investors in the biotech space should watch for full financial disclosures to gauge the sustainability of this positive surprise.
Source: dailypolitical.com · themarketsdaily.com
Zacks is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
